.jpeg)
Why is the targeted drug Pralsetinib not covered by medical insurance?
Pralsetinib (Pralsetinib) has been launched in China, but it has not yet entered the scope of medical insurance through the relevant regulations of the National Medical Insurance Bureau. Patients in need can currently only purchase it at their own expense. The price of each box of 100mg*120 tablets may be around RMB 60,000, which is expensive. For specific medical insurance information, please consult the local Medical Insurance Bureau and other places. Platinibis a daily oral targeted therapy that may block a protein called receptor transfection (RET). RET fusions lead to uncontrolled cell growth and cancer. By inhibiting RET, this drug can slow or prevent the growth of tumors. Common cancers containing RET fusions include non-small cell lung cancer (NSCLC) and thyroid cancer.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
